BioAge Labs aims to raise $180M from IPO, private placement to fund obesity trials
BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic. | BioAge Labs is eyeing about $180 million in initial proceeds from an IPO and a private placement,
Obesity-drug developer BioAge held on to a slim gain after rising more than 20%, while Texas-based Barnett Shale driller BKV ...
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO this morning, with the proceeds earmarked for taking its ...
BioAge Labs Inc., which has turned its aging diseases focus toward the hot area of obesity drugs, hopes to raise up to close ...
After BioAge Labs raised nearly $200 million in its IPO this week, several companies are beginning to eye the public markets, ...
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
Three IPOs each raised at least $100 million this week, in a welcome bump in activity. Read more here.
BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback